Shares of Danish drugmaker Novo Nordisk A/S (NVO) surged over 5% in pre-market trading on Friday following the company's announcement of positive topline results from a Phase 1b/2a clinical trial evaluating its investigational obesity drug amycretin.
The early-stage trial evaluated the safety, tolerability, and weight loss efficacy of once-weekly subcutaneous injections of amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in 125 individuals with overweight or obesity.
The results showed that amycretin exhibited a favorable safety profile consistent with other incretin-based therapies. More importantly, amycretin led to significant and dose-dependent weight loss, with patients in the highest 20mg dose group achieving an estimated 22% reduction in body weight over 36 weeks of treatment. In comparison, the placebo group experienced only a 2% weight gain over the same period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。